Quick Answer
Aurinia Pharmaceuticals Inc. reported Net Income Loss of $287.20 million for the year ending 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +4,893.1% in Net Income Loss from 2024 to 2025.
- This data is from Aurinia Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Aurinia Pharmaceuticals Inc.'s Net Income Loss has grown by 641.1%.
- Historical annual values: Fiscal year 2025: $287.20 million | Fiscal year 2024: $5.75 million | Fiscal year 2023: -$78.02 million | Fiscal year 2022: -$108.18 million | Fiscal year 2021: -$180.97 million | Fiscal year 2020: -$102.68 million | Fiscal year 2019: -$88.39 million | Fiscal year 2018: -$53.08 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: